Brief: Mabpharm Says New Drug Application Of CMAB009 Accepted By NMPA Of China
14/03/2023 15:14
March 14 (Reuters) - Mabpharm Ltd 2181.HK :
* NEW DRUG APPLICATION OF CMAB009 ACCEPTED BY NMPA OF CHINA
FOR
TREATMENT OF METASTATIC COLORECTAL CANCER
Source text for Eikon: ID:
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008